Clincierge™ Expands Clinical Concierge Services for Trial Participants and Families into 30th Country
PHILADELPHIA, July 28, 2015 /PRNewswire/ -- Clincierge™, the leading provider of specialized services and personalized support designed to overcome barriers to patient participation in clinical studies, today announced the expansion of its innovative "patient concierge" service into Cyprus. This event marks the 30th country where the company's high-touch, one-on-one services for patients and families are available to aid companies conducting clinical trials increase trial enrollment and improve patient retention, thus helping to ensure that costly studies complete on time and on budget.
"Since its inception two years ago, Clincierge has supported multiple studies internationally for pharmaceutical companies and contract research organizations with great success and overwhelming positive feedback from patients, research site personnel and sponsors," said Scott Gray, Clincierge chief executive officer. "By offering patients and their families personalized services in their own language from their own in-country coordinator, and providing patients ease-of-access to research sites, studies using Clincierge have seen increased enrollment and have maintained drop-out rates of less than 5%. Moreover, the cost of incorporating Clincierge services has averaged less than 1% to overall clinical trial costs."
Offering personalized support to trial participants and their families alleviates anxieties about trial-related travel, expenses and other issues that can get in the way of patients enrolling and staying in a clinical study. "The ultimate goal of Clincierge is to aid drug developers in reducing overall clinical testing time and cost by making clinical trials more patient-centric, thus helping ensure that new treatments get to the market and to patients who need them as swiftly as possible," Mr. Gray concluded.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
